Skip to main content

Ventripoint Diagnostics Ltd(VPT-X)
TSX Venture

Today's Change
Delayed Last Update
Day Low0.110
Day High0.115
Open:0.110
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change

Top Stories: Ventripoint Diagnostics Ltd

Select a category then submit the form to load news
Newswire.ca
Hospital Networks Turn to AI-Enhanced Cardiac Imaging to Cut Costs and Improve Outcomes
Newsfile
CEO.CA's Inside the Boardroom: Why Ventripoint is the Most Profitable "Bolt-On" Solution for Modern Hospitals
GlobeNewswire
THE SIGNAL ARCHITECTURE: 5 Stocks Calibrating the 2026 Infrastructure Cycle
GlobeNewswire
THE SOVEREIGNTY DOCTRINE: 5 Assets Locking Down the 2026 Survival Cycle
Newswire.ca
AI-Native Data Core Triggers Multi-Trillion Dollar Healthcare Structural Shift
BayStreet.ca
The 2026 Healthcare Reset: Subscription Economics Meets MRI-Grade AI Precision
Newswire.ca
AI Medical Imaging Revolution: Software-Native Tech Disrupts $45B Market
Baystreet
Stocks in play: Ventripoint Diagnostics Ltd
Newswire.ca
Bedside Breakthrough: AI Brings MRI-Precision to Every Clinic
GlobeNewswire
AI Diagnostics: The End of the High-Cost Imaging Era
GlobeNewswire
THE SCARCITY DOCTRINE: 5 Assets Securing the 2026 Material Cycle
BayStreet.ca
Medical Breakthroughs: 5 AI Innovators Redefining What's Possible
Baystreet
Stocks in play: Ventripoint Diagnostics Ltd
GlobeNewswire
THE FOUNDATION TRADE: 5 Assets Anchoring the Next Industrial Cycle
GlobeNewswire
THE VISIBILITY INDEX: 5 Companies Solving the Invisible Crisis
GlobeNewswire
Healthcare AI Exits Pilot Phase, Enters Production Deployment
Newswire.ca
AI Diagnostics Hit Critical Mass as Hospitals Race to Cut Costs
BayStreet.ca
Financial Pressure Turns Healthcare AI From Pilots Into Profits
GlobeNewswire
From Hype to P&L: Hospitals Now Buying AI That Pays
GlobeNewswire
THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality
GlobeNewswire
UPDATE -- The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
GlobeNewswire
The Efficiency Gap: Five Assets Where Price Has Yet To Reflect Reality
Newsfile
CEO.CA's Inside the Boardroom: Ventripoint Diagnostics: We Made Ultrasound as Good as MRI - Now Here's How We Scale It
AI-generated - The Globe and Mail
VentriPoint Diagnostics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (VPT)
Yolowire
AI-driven Cardiac Imaging Provider Sets Sights on Underserved CHD Population
Yolowire
VentriPoint: The Echo Play in AI Cardiac Imaging's Trillion-Dollar Convergence
Newsfile
CEO.CA's Inside the Boardroom: Cardiac MRI Alternative Gets FDA Nod - Ventripoint CEO on U.S. and China Sales Plans
Yolowire
The AI Revolution Could Get Traditional Ultrasound Machines To Produce MRI-Level Insights
AI-generated - The Globe and Mail
VentriPoint Diagnostics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (VPT)
AI-generated - The Globe and Mail
VentriPoint Diagnostics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (VPT)
AI-generated - The Globe and Mail
VentriPoint Diagnostics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (VPT)
AI-generated - The Globe and Mail
VentriPoint Diagnostics: Top 10 Undervalued Medical Devices & Instruments Industry Stocks (VPT)

Profile

VentriPoint Diagnostics Ltd is a medical device company engaged in the development and commercialization of diagnostic tools that monitor patients with heart disease. It develops applications for heart diseases and imaging modalities which includes congenital heart disease, left or right heart failure, and normal hearts. It sells its products in Canada and internationally.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2026 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.